Entest BioMedical Inc. (ENTB) Addresses COPD in a Multi-disciplinary Manner
25 Mar 2010

Entest BioMedical Inc. is making significant progress in the research and treatment of Chronic Obstructive Pulmonary Decease (COPD), explaining the constant rise of its stock price which reached on March 24, 2010 its highest close since October 2009 with $1,90 and a daily high at $ 1,95.

A day before, the company announced the filing of a patent application allowing the use of stem cell attracting molecules called chemokines in the treatment of COPD. Chemokines are naturally produced by the body and are essential for the healing process during tissue injuries. Entest’s new invention can enhance the efficiency of both existing and newly developed cell therapies, since it increases the number of stem cells attracted to the damaged tissue. The new method can be applied in cases of heart failure, liver failure and peripheral artery decease.

As another important part of Entest’s global strategy of addressing COPD, about a week earlier the company announced it is working on a new bioinformatics-based program combining the advances in molecular knowledge of COPD with computer-powered search tools in order to integrate existing and newly generated data. The program will create a database of all genes associated with COPD and will be using an automated algorithm to categorize these genes based on their biological functionality and their interrelations with each other. Over the analysis and the examination of the biochemical and biological data, new hypotheses about COPD can be developed and new applications for existing drugs may be found.

Additionally, on March 10, 2010 Entest BioMedical announced that Vladimir Bogin M.D., the CEO of Cromos Pharma LLC, a contract research organization (CRO), is joining Entest’s scientific advisory board. The company believes Dr. Bogin will contribute greatly to the COPD research model. Previously, on February 11, 2010 Entest applied for a project studying cancer stem cells, for which if approved, the company will receive up to $500,000 in funding over two years. Entest BioMedical also has launched a new corporate weblog, where the company’s management can communicate more efficiently with shareholders and potential investors.

No comments
Leave a comment

*
To prove you're a person (not a spam script), type the security word shown in the picture. Click on the picture to hear an audio file of the word.
Click to hear an audio file of the anti-spam word